EnteroMix Anticancer Vaccine Shows Early Promise

Author: Dr Azuka Chinweokwu Ezeike, MBBS, FWACS, FMCOG, MSc (PH)

EnteroMix, an anticancer vaccine, has just passed preclinical trials. This marks an important step in cancer research. The announcement was made by Veronika Skvortsova of the Federal Medical and Biological Agency (FMBA) at the Eastern Economic Forum held between September 3–6, 2025.

The preclinical trial (tests in the lab and on animals) demonstrated high safety and strong effectiveness. The vaccine may be useful both in treating existing cancers and in preventing them.

Vaccines are artificial substances that boost the body’s immunity, helping it fight infections. In recent years, researchers have also found ways to use vaccines in preventing and treating cancers.

What is EnteroMix?

Enteromix is an oncolytic multivirus vaccine developed by the National Medical Research Radiological Centre (NMRRC) of the Ministry of Health of the Russian Federation, in collaboration with the Engelhardt Institute of Molecular Biology, Russia.

How Was EnteroMix Developed?

The vaccine was created using four non-pathogenic (harmless) viruses. 

How Does EnteroMix Work?

Enteromix trains the immune system to recognise and attack cancer cells. This slows down the growth of tumours and can even destroy them.In preclinical testing, Enteromix led to a 60–80% reduction in tumour size, and repeated dosing was shown to be safe.

Clinical Trials

According to the NMRRC, the first phase of human clinical trials began with the recruitment of participants in late 2024 and early 2025. These early trials will mainly focus on safety and initial effectiveness.

Other Cancer Vaccines in Development

In addition to EnteroMix, the NMRRC, working together with the Gamaleya Institute, is also developing a personalised mRNA cancer vaccine.This vaccine is designed by studying the unique genetic makeup of each person’s cancer. By tailoring the vaccine to an individual’s cancer, it trains the person’s immune system to specifically recognise and fight their unique cancer cells.

Implications

If EnteroMix and the personalised mRNA vaccines work well in people (human trial), they could change how cancer is treated in the future. These new methods aim to help the body’s own immune system fight cancer, which may mean fewer side effects than traditional treatments like chemotherapy and radiation

Frequently Asked Questions (FAQ)

1. Is EnteroMix available now?

No. EnteroMix is still in the early stages of human clinical trials. It is not yet available for patients outside research studies.

2. How is Enteromix different from chemotherapy?

Chemotherapy kills fast-growing cells, including both cancer cells and healthy cells, which causes side effects. EnteroMix works by teaching the immune system to specifically target cancer cells, which may result in fewer side effects.

3. Can EnteroMix prevent cancer?

Researchers believe it may help in both prevention and treatment, but this has not yet been proven in humans. More studies are needed.

4. Who can get EnteroMix?

Currently, only people who are enrolled in clinical trials can receive EnteroMix. It is not yet approved for general use.

Sources: 

• National Medical Research Radiological Centre (NMRRC) of the MInistry of Health of the Russian Federation
• The Economic Times

Disclaimer:
The information provided on this website is for general educational and informational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Published September 8, 2025